Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal

Autor: Aa, Adjei, Ii, Budihardjo, Ek, Rowinsky, Tj, Kottke, Pa, Svingen, Ca, Buckwalter, Lb, Grochow, Rc, Donehower, Scott Kaufmann

Publikováno v: Europe PubMed Central

Pyrazoloacridine (PA), an acridine congener that has shown selective toxicity in solid tumor cells, full activity against noncycling and hypoxic cells, and promising activity in a recent Phase I trial, is currently undergoing Phase II testing as a so

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f1ea332ef7c5dcc7a56fa6fb696bd103
http://europepmc.org/abstract/med/9815747

Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

Autor: Budihardjo II; Division of Oncology Research, Mayo Medical School, Rochester, Minnesota, USA., Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2000 Mar; Vol. 57 (3), pp. 529-38.

Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody.

Autor: Budihardjo II; Division of Oncology Research, Mayo Clinic, and Mayo Medical School, Rochester, MN 55905, USA., Poirier GG, Kaufmann SH

Publikováno v: Molecular and cellular biochemistry [Mol Cell Biochem] 1998 Jan; Vol. 178 (1-2), pp. 245-9.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Autor: Adjei AA; The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, and Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA., Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 1997 May; Vol. 3 (5), pp. 761-70.